Genital herpes can be passed through direct contact with infected genital or oral skin, mucosa, sores, saliva, or genital fluids during vaginal, anal, or oral sex. Sores and warning symptoms are a higher-risk time, but transmission can also happen when no symptom is visible because HSV can be released from skin or mucosa without causing a noticeable outbreak. 1234
No single percentage can tell a person or couple their risk. HSV type and site, time since infection, symptoms, the contact involved, condom or barrier use, daily suppressive therapy, partner susceptibility, and the population behind the estimate all change what a study number means. Condoms and daily suppression can reduce risk in the settings where they have been studied, but neither makes risk zero. 125678910
The short version
| Situation | What the evidence supports | What it does not promise |
|---|---|---|
| Sores, a new lesion, or warning tingling, burning, or pain | Pause oral, vaginal, anal, and direct genital contact involving the affected area while those symptoms are present. This avoids a recognized higher-risk period. 123 | Symptom-based avoidance cannot prevent every transmission because shedding can occur without symptoms. 128 |
| No symptoms today | Transmission is still possible. Barriers can reduce direct contact, and people with symptomatic genital HSV-2 can discuss daily suppression with a clinician. 1234 | A symptom-free day does not show that no shedding is occurring. The directly estimated HSV-2 effects cited in this guide concern external condoms in the populations studied. 12678 |
| Symptomatic genital HSV-2 | A randomized transmission trial supports daily valacyclovir as one part of a risk-reduction strategy in the population it studied. 125 | The trial did not study every couple, every sexual practice, or medication taken only around sex. 5 |
| Genital HSV-1 | Genital shedding and recurrences are generally lower than with genital HSV-2 and shedding declined during the first year in a first-episode cohort. 129 | The shedding percentage is not a transmission rate, and suppressive therapy has not been studied for preventing genital HSV-1 transmission. 19 |
| Possible new genital HSV exposure during pregnancy | Contact an obstetric or sexual-health clinician promptly, especially later in pregnancy. 13 | General couple-study percentages are not pregnancy guidance. 13 |
How genital HSV is passed
HSV needs direct contact with an infected site. Genital HSV-2 is mainly passed through sexual contact with genital or anal skin, mucosa, sores, or fluids. HSV-1 can reach the genitals through oral sex when a partner has oral HSV-1, including when no cold sore is visible. 34
This means the relevant question is not only “Was there penetration?” Vaginal, anal, oral, and direct genital contact can expose different areas of skin or mucosa. The infected site matters: evidence about oral HSV-1, genital HSV-1, and genital HSV-2 cannot be treated as one interchangeable risk estimate. 134
Genital herpes is not spread through toilet seats, bedding, swimming pools, silverware, soap, or towels. 4
What asymptomatic shedding does and does not mean
“Shedding” means HSV is released from skin or mucosa. In research, it is often measured by taking repeated swabs and testing them for viral DNA. “Asymptomatic” or “subclinical” shedding means the virus was detected when no lesion or recognized symptom was present. 289
One HSV-2 study followed 498 immunocompetent people who collected daily genital swabs. HSV-2 was detected on 20.1% of sampled days among people with recognized symptomatic genital HSV-2 and 10.2% among people who considered themselves asymptomatic. On days without lesions, it was detected on 13.1% and 8.8% of sampled days, respectively. 8
Those figures are not the chance of passing HSV during sex. They describe how often a PCR test detected HSV in groups of research participants. The study did not track whether a susceptible partner acquired HSV after each sampled day. A shedding-day percentage, a per-act transmission estimate, and a partner's acquisition over months are different measurements. 589
Symptoms still matter. Current European and WHO guidance describes lesions, sores, and prodromal warning symptoms as the highest-risk period. Avoiding contact then removes a known higher-risk window. It cannot remove all risk because symptom-free shedding also occurs. 123
The checked CDC and European guidelines do not establish a universal countdown after a sore heals that makes transmission risk zero. They support avoiding sexual contact while lesions or prodromal symptoms are present, then using the couple's chosen risk-reduction measures during symptom-free periods. 12
Why HSV-1 and HSV-2 need different answers
Genital HSV-1 and genital HSV-2 can cause a similar first episode, but their longer-term patterns differ. Genital HSV-2 generally recurs and sheds more often. Genital HSV-1 usually recurs and sheds less, and its genital shedding declines more quickly during the first year. 12
In a prospective study of 82 people after first-episode genital HSV-1, HSV-1 was detected on 12.1% of sampled genital-swab days at two months and 7.1% at eleven months. The participants did not have HIV and were not currently pregnant. The study measured shedding during selected sampling periods; it did not measure transmission to partners. 9
That distinction prevents two opposite errors. It would be wrong to apply the better-known HSV-2 couple percentages to genital HSV-1. It would also be wrong to turn lower genital HSV-1 shedding into a claim that transmission is impossible or below a named percentage. Current CDC guidance says suppressive therapy's effect on genital HSV-1 transmission has not been studied. 19
Time matters for HSV-2 as well. CDC states that asymptomatic shedding is most frequent during the first 12 months after acquiring HSV-2. Shedding can continue after that; the first year is not a cutoff after which risk disappears. 1
What lowers transmission risk
The evidence supports layers, each with a limit:
- Pause during symptoms. Avoid sexual contact involving the affected area when sores, lesions, or prodromal warning symptoms are present. This addresses a higher-risk period but not symptom-free shedding. 123
- Use an appropriate barrier consistently. The directly estimated HSV-2 effects cited here concern external condoms, and uncovered skin can still shed HSV. Other barriers may reduce skin or mucosal contact, but the checked evidence does not provide a comparable HSV-specific percentage for them or for every sexual practice. 12367
- Discuss daily suppression for symptomatic genital HSV-2. Daily valacyclovir reduced transmission in a randomized trial, but the study population and regimen matter. 125
- Know which question remains unanswered. A partner conversation can address HSV type and site, current symptoms, barriers, treatment, pregnancy, and whether a separate clinical testing question might clarify HSV-2 susceptibility. It cannot manufacture a zero-risk promise. 14
These layers should not be turned into arithmetic. The condom and antiviral percentages came from different study designs and conditions. The antiviral trial did not randomly assign couples to every combination of condoms, no condoms, treatment, and no treatment. Multiplying separate relative reductions does not produce a validated personal risk. 567
What the antiviral transmission trial actually found
The pivotal direct medication trial was published in 2004. It followed 1,484 immunocompetent, heterosexual, monogamous couples in which one partner had clinically symptomatic genital HSV-2 and the other was susceptible to HSV-2. The source partner took daily valacyclovir or placebo for eight months. Both partners received safer-sex counseling and were offered condoms. 5
| Trial outcome over eight months | Daily valacyclovir | Placebo | What the number means |
|---|---|---|---|
| Any laboratory-documented HSV-2 acquisition | 14 of 743 partners, or 1.9%. 5 | 27 of 741 partners, or 3.6%. 5 | Overall acquisition in this selected trial population, not a universal annual risk. 5 |
| Symptomatic genital herpes | 4 of 743 partners. 5 | 16 of 741 partners. 5 | The trial's primary symptomatic endpoint, which is different from all laboratory-documented acquisition. 5 |
The trial establishes that daily valacyclovir reduced transmission in that setting. It does not show that treatment eliminated risk. It also does not establish the same percentage for genital HSV-1, HSV-2 diagnosed only by a blood test in someone who has never had symptoms, people with HIV, pregnancy, non-monogamous relationships, same-gender couples, or every oral or anal exposure. 125
The dosing pattern is part of the evidence. The trial studied daily therapy for eight months. It did not test a pill taken only the day before sex or only when sex was expected. CDC also separates episodic treatment, which is used to shorten a recurrence, from daily suppressive therapy used as part of transmission prevention. 15
For a partner who does not have HSV-2, CDC does not recommend acyclovir, valacyclovir, or famciclovir as pre-exposure or post-exposure medication to prevent acquisition because supporting data are not available. 1
What condoms can and cannot do
Condoms reduce HSV risk when they cover the infected area or site of exposure. They cannot cover all genital or anal skin, which is why the evidence supports “reduce” rather than “prevent completely.” 134
A 2009 pooled analysis combined six prospective studies and 5,384 people who were HSV-2-negative at enrollment. People reporting condom use for every sex act had a 30% lower adjusted risk of HSV-2 acquisition than people reporting no condom use. Condom use was self-reported and not randomly assigned, and the six studies differed in purpose and population. A later correction fixed an x-axis distribution in one figure; it did not replace the main estimate. 6
A separate per-act analysis in 911 African heterosexual couples discordant for HIV-1 and HSV-2 found a strong protective association for male-to-female transmission and a smaller, statistically marginal association for female-to-male transmission. CDC and European guidance also describe stronger or easier-to-demonstrate protection in the male-to-female direction, while the larger 2009 pooled analysis did not find a significant gender interaction. 1267
The responsible conclusion is stable even though the direction-specific numbers differ: consistent condom use offers partial protection, and the size of that protection cannot be assigned to every couple. The direct evidence is strongest for external condoms and HSV-2 in the populations studied. A barrier used for oral, anal, or other sexual contact may reduce direct contact, but the checked evidence does not supply one HSV-specific percentage for every barrier, anatomy, or practice. 1267
Where the annual percentages come from
Numbers commonly repeated online often lose the details that made them meaningful. Two important couple studies show why context cannot be removed.
| Study | Population and timeframe | What happened | Why it is not your personal annual percentage |
|---|---|---|---|
| 1992 prospective couple study | 144 heterosexual couples; source partner had symptomatic recurrent genital herpes; susceptible partner had no clinical or serologic evidence of genital herpes; median follow-up 334 days. 10 | Transmission occurred in 14 couples: 11 of 65 male-source couples and 3 of 79 female-source couples. Nine of 13 transmissions with detailed histories appeared to occur while the source partner was asymptomatic. 10 | Small clinic-based cohort using historical testing and counseling. The result varied by sex direction and partner antibody status. 10 |
| 2004 daily-valacyclovir trial | 1,484 immunocompetent heterosexual monogamous HSV-2-discordant couples; symptomatic HSV-2 source partner; eight months; safer-sex counseling and condoms offered. 5 | Overall acquisition was 3.6% with placebo and 1.9% with daily valacyclovir. 5 | Eight months, not a year; selected couples; specific treatment assignment; counseling and barrier availability; genital HSV-2 rather than genital HSV-1. 5 |
Both studies produced real observations. Neither created a rule that applies unchanged to a new couple. Frequency and kind of sexual contact, HSV type and site, how recently infection was acquired, current symptoms, partner susceptibility, barrier use, daily suppression, pregnancy, HIV status, and the study's endpoint all affect interpretation. 125678910
A percentage should always be read with four labels:
- Who was studied? HSV type, symptoms, health status, partner status, sex and relationship structure.
- What was measured? A positive swab, symptomatic disease, laboratory acquisition, person-time, or a sex act.
- For how long? Days, months, a median follow-up, or a full year.
- Under what conditions? Condoms, counseling, medication, frequency of sex, and study eligibility.
If those labels are missing, the number is not ready to guide a personal decision.
Oral sex and other evidence gaps
Oral HSV-1 can cause genital HSV-1 through oral sex, including when no cold sore is visible. Active oral or genital sores are a higher-risk time, so contact involving that site should pause while symptoms are present. 34
For someone who already has genital HSV-1, the first-episode shedding study helps explain why time since infection matters. It does not tell us a precise genital-to-oral or genital-to-genital chance per act. The checked evidence also does not produce a reliable personal percentage for dental dams, internal condoms, anal sex, same-gender couples, transgender people, or combinations of anatomy and HSV site that were not represented in the major studies. 1279
An evidence gap is not the same as zero risk. It means the most honest answer may be: transmission is biologically possible, type and site matter, barriers can reduce direct contact, symptoms identify a higher-risk period, and a precise route-specific percentage has not been established.
A practical partner conversation
The useful conversation is not “Can you promise this is safe?” No general guide can do that. It is:
- Which HSV type and body site are known?
- Are there sores or warning symptoms today?
- Which sexual contact are we considering, and which skin or mucosa would be exposed?
- Which barrier fits that contact, and what would it cover?
- If this is symptomatic genital HSV-2, has daily suppression been discussed with a clinician?
- Is pregnancy, possible new infection, HIV, or significant immune suppression part of the situation?
- Is there a testing question that should be handled before treating either partner as susceptible or infected?
- What level of remaining uncertainty are both partners comfortable accepting?
Talking does not biologically stop shedding. It lets both people make informed choices about a risk that can be reduced but not always calculated or eliminated. Current guidance recommends informing partners; a full disclosure guide should address the relationship conversation separately. 134
When this general guide is not enough
Seek individualized clinical guidance rather than relying on general couple-study numbers when:
- a pregnant person may have newly acquired genital HSV or has a partner with HSV, especially later in pregnancy 13
- HIV or significant immune suppression may change symptoms, shedding, or treatment context 13
- lesions are severe, persistent, unusual, or accompanied by signs of serious illness 13
- the HSV type or infection site is uncertain and that uncertainty is driving a major decision 14
- a person is considering starting, stopping, or changing suppressive medication 12
This guide explains evidence. It cannot diagnose infection, choose treatment, or calculate a personal transmission probability from incomplete circumstances.
Evidence and sources
Evidence scope: Current CDC, European, and WHO guidance; pivotal partner-transmission and condom studies; daily-swab studies of symptomatic and asymptomatic HSV-2; and the prospective first-episode genital HSV-1 shedding cohort.
Important limitations: Direct partner-transmission evidence centers on genital HSV-2 in immunocompetent heterosexual couples. Evidence is more limited for genital HSV-1, oral or anal routes, internal condoms or dental dams, same-gender couples, transgender people, pregnancy, people with HIV, and significant immune suppression. No validated personal calculator was identified, and the checked guidelines do not establish a universal post-outbreak waiting interval.
Sources
- CDC. Sexually Transmitted Infections Treatment Guidelines, 2021: Genital Herpes (opens in a new tab)Return to citation
- Patel R, et al. 2024 European guidelines for the management of genital herpes (opens in a new tab)
DOI: 10.1111/jdv.20450
Return to citation - World Health Organization. Herpes simplex virus (opens in a new tab)Return to citation
- CDC. About Genital Herpes (opens in a new tab)Return to citation
- Corey L, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes (opens in a new tab)
DOI: 10.1056/NEJMoa035144
Return to citation - Martin ET, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition (opens in a new tab)
DOI: 10.1001/archinternmed.2009.177
Return to citation - Magaret AS, et al. Effect of condom use on per-act HSV-2 transmission risk in HIV-1, HSV-2-discordant couples (opens in a new tab)
DOI: 10.1093/cid/civ908
Return to citation - Tronstein E, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection (opens in a new tab)Return to citation
- Johnston C, et al. Viral shedding 1 year following first-episode genital HSV-1 infection (opens in a new tab)Return to citation
- Mertz GJ, et al. Risk factors for the sexual transmission of genital herpes (opens in a new tab)
DOI: 10.7326/0003-4819-116-3-197
Return to citation
Read the herpes-testing guide, see how HSVHQ handles evidence and review, browse the HSV research tracker, or report a possible correction.